Analyst Price Targets — PODD
| Date | Analyst | Firm | Target | Price @ Post | Source | Headline |
|---|---|---|---|---|---|---|
| April 15, 2026 12:41 pm | Richard Newitter | Truist Financial | $315.00 | $202.28 | TheFly | Insulet price target lowered to $315 from $360 at Truist |
| April 14, 2026 11:24 am | Shagun Singh | RBC Capital | $325.00 | $197.81 | TheFly | Insulet price target lowered to $325 from $380 at RBC Capital |
| February 19, 2026 2:04 pm | — | Truist Financial | $360.00 | $246.04 | TheFly | Insulet price target lowered to $360 from $390 at Truist |
| February 19, 2026 1:19 pm | — | Evercore ISI | $340.00 | $251.21 | TheFly | Insulet price target lowered to $340 from $370 at Evercore ISI |
| February 19, 2026 12:58 pm | David Roman | Goldman Sachs | $326.00 | $251.38 | TheFly | Insulet price target lowered to $326 from $363 at Goldman Sachs |
| February 19, 2026 12:46 pm | — | Oppenheimer | $300.00 | $254.59 | TheFly | Insulet price target lowered to $300 from $365 at Oppenheimer |
| February 19, 2026 12:38 pm | — | Bernstein | $330.00 | $258.07 | TheFly | Insulet price target lowered to $330 from $380 at Bernstein |
| February 19, 2026 11:35 am | — | Barclays | $286.00 | $258.07 | TheFly | Insulet price target raised to $286 from $274 at Barclays |
| February 18, 2026 9:43 pm | William Plovanic | Canaccord Genuity | $435.00 | $258.07 | StreetInsider | Insulet Corporation (PODD) PT Lowered to $435 at Canaccord Genuity |
| February 4, 2026 1:09 pm | — | Stifel Nicolaus | $350.00 | $249.07 | TheFly | Insulet price target lowered to $350 from $370 at Stifel |
Latest News for PODD
We are actively monitoring Meta Platforms' social and data privacy risks and believe the company has made progress on strengthening its policies and enforcement. We believe the market is underestimating the durability of Edwards' transcatheter aortic valve replacement franchise and the opportunity for its transcatheter mitral and tricuspid therapies. We exited our position in Workday to bring the portfolio's…
NEW YORK, April 16, 2026 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of Insulet Corporation ("Insulet" or the "Company") (NASDAQ: PODD). Such investors are advised to contact Danielle Peyton at newaction@pomlaw.com or 646-581-9980, ext.
Insulet Corp. Stock Falls After Voluntary Medical Device Correction Reveals Omnipod 5 Insulin-Leakage Defect Affecting Thousands of Pods NEW YORK, April 15, 2026 /PRNewswire/ -- Insulet Corp. (NASDAQ: PODD) shares dropped approximately 6.9% after the Company filed an 8-K on March 12, 2026, disclosing a voluntary medical device correction covering Omnipod 5 insulin pods due to a design defect that could cause insulin…
NEW YORK, April 14, 2026 (GLOBE NEWSWIRE) -- Pomerantz LLP is investigating claims on behalf of investors of Insulet Corporation (“Insulet” or the “Company”) (NASDAQ: PODD). Such investors are advised to contact Danielle Peyton at newaction@pomlaw.com or 646-581-9980, ext. 7980.
Investors interested in Medical - Products stocks are likely familiar with Phibro Animal Health (PAHC) and Insulet (PODD). But which of these two stocks offers value investors a better bang for their buck right now?
🧮 Earnings Move Analyzer
Insider Trading
Insider Trading
| Name | Role | Date | Type | Shares | Price | Form | Link |
|---|
Senate Trading
Senate Trading Disclosures
| Name | Transaction Date | Type | Asset | Amount | Link |
|---|
U.S. House Trading
House Trades Disclosures
| Name | Transaction Date | Type | Asset | Amount | Link |
|---|
Options Chain
Select an expiration to expand. Bid/Ask are shown first (before Mark) on both sides.